Our CEO Joanna Shields is presenting at the Times Tech Summit on why we need to use AI for life, not just lifestyle.
We hear so much about how technology is transforming life as we know it -- from autonomous vehicles to the likely prospect of space travel to Mars -- so why then does the treatment of disease still represent one of the greatest unmet human needs?
BenevolentAI today announces the appointment of Dr. Susan Liautaud as a member of the board of directors of the Company with effect from 30 June 2022. Dr. Susan Liautaud will act as Independent Non-Executive Director of the Company.
BenevolentAI, a leading, clinical-stage AI-enabled drug discovery company, announces that trading in its shares is expected to begin today, following completion of its business combination with Odyssey Acquisition S.A. on 22 April 2022.
Advanced technologies, combined with an exponential increase in biomedical data and research, provide an unparalleled opportunity to unravel the mysteries of diseases that have gone untreated for too long.
BenevolentAI joins the World Economic Forum’s Global Innovators Community to help ethically deploy AI to create a more sustainable, inclusive and resilient world.
